Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  trastuzumab
Find trials that include:  Any drugs shown
Results 1-25 of 50 for your search:
Start Over
MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MM-302-02-02-03, NCI-2014-02093, NCT02213744
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CP-MGAH22-04, NCI-2016-00295, NCT02492711
Trastuzumab in Treating Leptomeningeal Metastases in Patients with HER2-Positive Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 10C03, NCI-2011-00110, STU00040150, STU00040150-MOD0003, NCT01325207
Vaccine Therapy with or without Polysaccharide-K in Treating Patients with Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 7866, NCI-2013-01377, 135, 7866/135, NCT01922921
Gemcitabine Hydrochloride, Trastuzumab, and Pertuzumab in Treating Patients with Previously Treated HER2-Positive Metastatic Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MCC-17656, NCI-2014-01935, 14.01.0062, 280513, Genentech ML28939, ML28939, NCT02139358
Ribociclib with Trastuzumab or Trastuzumab Emtansine in Treating Patients with Locally Advanced or Metastatic HER2-Positve Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Tissue collection/Repository
Age: 18 and over
Trial IDs: 15-530, NCI-2016-00505, NCT02657343
Carboplatin, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, and Bevacizumab or Trastuzumab Before Surgery in Treating Women With Stage I-III Breast Cancer
Status: Temporarily closed
Phase: Phase II
Type: Treatment
Age: 21 to 90
Trial IDs: UCI-07-61, NCI-2010-00155, 2007-6084, NCT00618657
Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Stage IV Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J0947, NCI-2010-02004, NA_00024527, JHOC-J0947, GENENTECH-JHOC-J0947, NCT00971737
I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 097517, NCI-2015-00014, NCT01042379
Everolimus, Trastuzumab, and Vinorelbine Tartrate in Treating Patients With Progressive HER2-Positive Breast Cancer and Brain Metastases
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and over
Trial IDs: LCCC 1025, NCI-2013-01079, 11-0242, NCT01305941
Carboplatin and Paclitaxel With or Without Trastuzumab in Treating Patients With HER2-Positive Stage III-IV or Recurrent Uterine Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: Not specified
Trial IDs: 1012007786, NCI-2013-00894, NCT01367002
Neratinib, Capecitabine, and Trastuzumab in Treating Patients with HER2-Positive Breast Cancer That Has Spread to the Brain
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-344, NCI-2012-00255, TBCRC 022, NCT01494662
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Status: Active
Phase: Phase II
Type: Prevention
Age: 18 and over
Trial IDs: 368255, NCI-2015-00026, 1137008 / 20130058, NCT01570036
Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients with HER2-Positive Stage II-IV Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 12147, NCI-2012-02371, 105932, 109681, 119638, NCT01730833
Paclitaxel and Cyclophosphamide with or without Trastuzumab before Surgery in Treating Patients with Previously Untreated Stage I-III Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 264-12, NCI-2012-01372, NCT01750073
Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients with ERBB2 Expressing Disseminated Tumor Cells
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 201309084, NCI-2012-03110, 12-X356, NCT01779050
Paclitaxel, Trastuzumab, and Pertuzumab before Surgery in Treating Patients with Inflammatory Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-497, NCI-2013-01110, ML28193, NCT01796197
Trastuzumab Emtansine or Paclitaxel and Trastuzumab in Treating Patients with Stage I HER2-Positive Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13-048, NCI-2013-01818, ML28160, TBCRC 033, NCT01853748
Pertuzumab and Trastuzumab with Combination Chemotherapy before Surgery in Treating Patients with Stage I-III HER2 Positive Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 65
Trial IDs: 1305012136, NCI-2015-02018, ML28772, NCT01855828
Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients with HER2-Positive Metastatic Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 1B-12-10, NCI-2013-01086, HS-13-00084, NCT01873833
Eribulin Mesylate, Trastuzumab, and Pertuzumab in Treating Patients with HER2-Positive Breast Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-163, NCI-2013-01826, 688097, 707389, NCT01912963
Stereotactic Radiosurgery Followed by HER2 Directed Therapy in Treating Patients with HER2 Positive Breast Cancer with Newly Diagnosed Brain Metastasis
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 1345GCC, NCI-2015-02007, NCT01924351
Combination Chemotherapy in Treating Patients with Advanced Stomach, Gastroesophageal, or Esophageal Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 201309035, NCI-2013-01783, NCT01928290
Radiation Therapy and Sequential or Concurrent Combination Chemotherapy in Treating Patients with Estrogen Receptor-Negative Early Stage Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: J13104, NCI-2013-02402, CIR00000810, NA_00086037, NA_00086037 / CIR00009481, NCT01928589
Start Over